Zimbabwe has turned down a substantial US health deal worth $367m (£272m) spanning five years due to the United States' request for confidential biological samples.
This move came to light following a government memo from December was leaked, revealing that President Emmerson Mnangagwa felt the deal was "lopsided".
An official spokesman has since explained that the US was demanding access to biological samples for scientific study and commercial gain but was unwilling to share the resulting advantages from any future treatments.
"We will now turn to the challenging and unfortunate process of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had provided over $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further dialogue to reach a deal acceptable to both sides so the country's vital HIV programme can proceed.
Wider Implications
This development follows a comparable case in neighbouring Kenya, where a court blocked a related deal with the US after legal challenges were filed about the security of citizens' medical information.
Since returning to office last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had overseen aid for the US government, but Trump stated its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to enhance transparency and accountability.
Based on statements, Sixteen nations in Africa have so far signed these new health pacts, representing more than $18.3bn in committed funds.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment through US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its biological resources and data for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," Mangwana explained.
"In essence, our nation would provide the basic resources for medical research with no certainty that the resulting innovations would be accessible to our people should a future health crisis arise."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining frameworks already established through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to manage future pandemics.
"This framework is designed to guarantee that when a country contributes its information, the resulting advantages – such as vaccines and treatments – are distributed fairly, not monopolised solely by those with the resources to develop them."
These objections over the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how subsequent co-operation might be structured in a way that honours the independence and dignity of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but recommended that negotiations need to persist given that a large portion of the nation's HIV programmes relied on external financing.
"In cases where technical issues arise, such as those relating to information security or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," it said.
This impasse underscores the ongoing debate between receiving vital foreign assistance and safeguarding local interests in an increasingly data-driven world.